NCT04629339

Study of INCB086550 in Select Solid Tumors

A Phase 2 Study of INCB086550 (Oral PD-L1 Inhibitor) in Participants Who Are Immune Checkpoint Inhibitor-Naïve With Selected Solid Tumors

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in participants with select solid tumors

Conditions

• Non Small Cell Lung Cancer
• Urothelial Cancer
• Renal Cell Carcinoma
• Hepatocellular Carcinoma
• Melanoma

Interventions

Type	Name	Description
DRUG	INCB086550	INCB086550 will be administered orally twice a day.

Timeline

• Start date: 2021-09-02
• Primary completion: 2024-03-26
• Completion: 2024-03-26
• First posted: 2020-11-16
• Last updated: 2025-03-13
• Results posted: 2025-03-13

Locations

20 sites across 5 countries: Bulgaria, Hungary, South Korea, Taiwan, Ukraine

Regulatory

• FDA-regulated drug study